Ibrutinib and novel BTK inhibitors in clinical development

Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease

(2013) Rakesh Bam et al.   AMERICAN JOURNAL OF HEMATOLOGY

MEK and the inhibitors: from bench to bedside

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

B-Raf and the inhibitors: from bench to bedside

(2013) Tiangui Huang et al.   Journal of Hematology & Oncology

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

(2012) M. F. M. de Rooij et al.   BLOOD

Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy

(2012) Joseph J. Buggy et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel targeted agents for gastric cancer

(2012) Lian Liu et al.   Journal of Hematology & Oncology

Recent advances and novel agents for gastrointestinal stromal tumor (GIST)

(2012) Gurpreet Lamba et al.   Journal of Hematology & Oncology

Therapeutic advancement of chronic lymphocytic leukemia

(2012) Kang Lu et al.   Journal of Hematology & Oncology

Current management and novel agents for malignant melanoma

(2012) Byung Lee et al.   Journal of Hematology & Oncology

Novel CD20 monoclonal antibodies for lymphoma therapy

(2012) Shundong Cang et al.   Journal of Hematology & Oncology

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

(2012) Jack Hutcheson et al.   ARTHRITIS RESEARCH & THERAPY

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

(2011) S. Ponader et al.   BLOOD

Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase Inhibitor

(2011) L. Liu et al.   DRUG METABOLISM AND DISPOSITION

Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy

(2011) L. Liu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

More than just B-cell inhibition

(2011) Eric M Ruderman et al.   ARTHRITIS RESEARCH & THERAPY

BRAF Inhibitors: Research Accelerates in Wake of Positive Findings

(2010) V. Brower   JNCI-Journal of the National Cancer Institute

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

(2009) Abdalla J. Mohamed et al.   IMMUNOLOGICAL REVIEWS

Large-scale Proteomics Analysis of the Human Kinome

(2009) Felix S. Oppermann et al.   MOLECULAR & CELLULAR PROTEOMICS

Multiple Colorectal Neoplasms in X-Linked Agammaglobulinemia

(2007) Lodewijk A.A. Brosens et al.   Clinical Gastroenterology and Hepatology